Antitubercular Agents

High-yield Verified · Jul 2026

Prototype: isoniazid

The RIPE regimen — isoniazid, rifampin, pyrazinamide, ethambutol — treated together to outrun resistance.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 Why TB needs multiple drugs for months

Mycobacterium tuberculosis is slow-growing, hides inside cells, and mutates readily — so a single drug quickly selects resistant survivors. The solution is to hit it with several drugs at once for a long time: the standard RIPE regimen (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) for the first 2 months, then rifampin + isoniazid to complete 6 months. Using multiple agents makes it statistically almost impossible for a single organism to be resistant to all of them.

Because the course is long and the drugs are toxic, adherence is the whole game — non-adherence breeds multidrug-resistant TB, which is why directly observed therapy (DOT) is often used.

02 Each drug’s signature toxicity

The RIPE drugs share one theme — hepatotoxicity (isoniazid, rifampin, and pyrazinamide are all hard on the liver, so LFTs and alcohol are watched) — but each has a distinctive fingerprint. Isoniazid depletes vitamin B6 (pyridoxine), causing peripheral neuropathy — so B6 is given alongside it. Rifampin turns body fluids orange-red (urine, tears, sweat — harmless, but stains contact lenses) and is a potent CYP450 inducer that speeds up metabolism of many drugs (warfarin, oral contraceptives, HIV meds).

Pyrazinamide raises uric acid (can trigger gout) and is hepatotoxic. Ethambutol causes optic neuritis — declining visual acuity and red-green color discrimination — so baseline and periodic vision testing is done, and patients report any vision change.

Loading diagram…

RIPE: a shared hepatotoxicity plus one signature toxicity per drug.

Drug names

Generic Brand

isoniazid (INH) —

rifampin Rifadin

pyrazinamide —

ethambutol Myambutol

Indications

Active tuberculosis (multi-drug RIPE regimen)
Latent TB infection (isoniazid ± rifampin, or rifampin alone)
Some non-tuberculous mycobacterial and other infections (rifampin)

Mechanism of action

Combination therapy against M. tuberculosis: isoniazid inhibits mycolic-acid (cell-wall) synthesis; rifampin inhibits bacterial RNA polymerase; pyrazinamide disrupts membrane energetics in acidic environments; ethambutol inhibits arabinosyl transferase (cell-wall). Multiple agents prevent resistance.

In plain terms

Several TB drugs attack the bacteria different ways at once — for months — so it can’t become resistant.

Therapeutic effects — what you'll see working

Success is culture conversion and cure over months. The nursing focus is adherence (DOT), monitoring the liver, and the drug-specific toxicities (B6, vision, orange fluids, interactions).

TB cure Resistance prevention

TB cure: Sustained multi-drug therapy sterilizes the infection and prevents relapse and transmission.
Resistance prevention: Combining agents ensures no single organism survives all of them — the core reason for multi-drug therapy.

Adverse effects

The shared danger is hepatotoxicity; the memorable part is each drug’s signature effect (neuropathy, orange fluids/CYP induction, hyperuricemia, optic neuritis).

Common Expected

GI upset; orange-red urine/tears/sweat (rifampin — harmless); isoniazid tingling/numbness; arthralgia (pyrazinamide).

Reassure about rifampin’s orange discoloration (warn it stains soft contact lenses). Isoniazid neuropathy is prevented with pyridoxine (B6).

Serious Hold & notify

Hepatotoxicity (INH, rifampin, pyrazinamide); optic neuritis (ethambutol); isoniazid peripheral neuropathy; hyperuricemia/gout (pyrazinamide); rifampin drug interactions (CYP450 induction).

Watch for hepatitis (nausea, dark urine, jaundice, RUQ pain) — monitor LFTs and avoid alcohol. Ethambutol optic neuritis requires baseline/periodic vision and color testing. Rifampin induces CYP450, reducing levels of warfarin, oral contraceptives, and many other drugs.

Interactions

Warfarin, oral contraceptives, HIV meds & many others (rifampin) drug

Rifampin is a strong CYP450 enzyme inducer — it speeds metabolism and lowers levels of warfarin, oral contraceptives, and many drugs, risking therapeutic failure; advise a backup contraceptive method.

Contraindications

The cautions are liver disease, the eye (ethambutol), and drug interactions (rifampin).

Active/severe hepatic disease

Isoniazid, rifampin, and pyrazinamide are hepatotoxic and can worsen liver injury.

Optic neuritis / inability to report vision changes (ethambutol) use caution

Ethambutol can cause vision loss that must be caught early by symptom reporting.

Drugs dependent on CYP450 (warfarin, oral contraceptives, HIV protease inhibitors) — rifampin use caution

Rifampin induces metabolism and can cause therapeutic failure of these drugs (use backup contraception).

Labs & levels

Test Therapeutic / normal Toxic / critical

Liver function tests (AST/ALT, bilirubin) Baseline & periodically — **isoniazid, rifampin, and pyrazinamide are hepatotoxic**; hold and notify for symptomatic hepatitis (nausea, dark urine, jaundice, RUQ pain). Normal range AST 10–40 · ALT 7–56 U/L · bilirubin < 1.2 mg/dL —

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Adherence & monitoring

Support adherence (often DOT); monitor LFTs and teach signs of hepatitis; avoid alcohol.

Why: Non-adherence breeds resistance; three of the four drugs are hepatotoxic.

Give pyridoxine (B6) with isoniazid; arrange baseline/periodic vision & color testing for ethambutol.

Why: B6 prevents INH neuropathy; ethambutol optic neuritis must be detected early.

Patient teaching

Reassure that orange-red urine/tears/sweat (rifampin) is harmless but stains contacts; use backup contraception.

Why: Prevents alarm; rifampin induces metabolism of oral contraceptives.

Report vision changes, numbness/tingling, or jaundice/nausea promptly.

Why: These flag optic neuritis, neuropathy, and hepatotoxicity.

Sources

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.